A dark horse effort to treat Alzheimer’s disease, already marred by a data manipulation scandal, fell short in a randomized trial reported Tuesday afternoon. Athira
NEW YORK — Sixteen floors above Central Park, Kris White keeps his gentler pathogens behind an unlocked stainless steel freezer door, in brightly colored boxes
High-profile gene editing startup Tome Biosciences said in a legal filing Friday that it will terminate virtually its entire staff beginning Nov. 1. The Massachusetts
The National Institutes of Health said Thursday that an antiviral often used to treat mpox did not resolve patients’ symptoms faster than placebo in a
A decade ago, Pfizer began investing heavily in gene therapy, bringing in experimental treatments for a range of genetic diseases, pumping $800 million into “state-of-the-art”
Pfizer said Wednesday that its gene therapy for hemophilia A successfully reduced patients’ bleeds for at least 15 months in a large phase 3 trial.
Lexeo Therapeutics said Monday that a gene therapy designed to prevent fatal cardiac complications of a genetic disorder called Friedrich’s ataxia reduced signs of heart
In a long-awaited study, patients in Australia will soon receive an IV infusion designed to transform their own immune cells into swarms of cancer-fighting drones.
Sonia Vallabh always thought genome editing wouldn’t be an option. It was such an obvious solution that people invariably asked, “What about CRISPR?” at the
As chief medical officer of Moderna, Tal Zaks used to be skeptical of genome editing. Why repair a patient’s broken gene, he would ask, with